Publications by authors named "Anthony DelConte"
Article Synopsis
- - Sarcopenia, a condition involving muscle loss, is common in men with liver cirrhosis and has negative effects on health, including increasing the risk of hepatic encephalopathy (HE); androgen receptor agonists (ARAs) like LPCN 1148 show potential to address these issues but their effectiveness and safety in this demographic were previously unclear.
- - In a phase 2 trial, men with cirrhosis and sarcopenia were given either LPCN 1148 or placebo for 24 weeks, with results indicating that those taking LPCN 1148 had a significant increase in muscle mass (measured by CT scans) and experienced fewer episodes of serious HE compared to the placebo group.
Background: Male hypogonadism (testosterone level < 300 ng/dl) is a clinical syndrome that results from failure of the testis to produce physiological levels of testosterone. Most marketed testosterone replacement therapy products often require multiple dose adjustment clinic visits to achieve the desired, eugonadal testosterone levels.
Objective: To evaluate the efficacy and safety of a novel oral testosterone undecanoate therapy for the treatment of hypogonadism.
Effects of a Novel Oral Testosterone Undecanoate on Ambulatory Blood Pressure in Hypogonadal Men.
J Cardiovasc Pharmacol Ther
November 2021
Article Synopsis
- Testosterone replacement therapies, like TLANDO™, may raise blood pressure (BP) over time, particularly in men with hypogonadism, as shown in a study of 138 participants with a mean age of 54.
- After 4 months of treatment at 225 mg twice daily, significant increases in ambulatory systolic BP during various times were noted, indicating a potential link between testosterone therapy and BP elevations.
- Higher changes in hematocrit levels were associated with greater increases in BP, suggesting that monitoring hematocrit might help predict BP changes in patients undergoing testosterone therapy.
The efficacy, safety, and cycle control of a low-dose oral contraceptive (OC) containing 20 microg ethinyl estradiol (EE) and 100 microg levonorgestrel (LNG) has been demonstrated in a large trial with 1708 women (>or=15 years old with regular menstrual cycles). The objective of this study was to analyze the same parameters in 218 of the 1708 women who were 35 years of age and older. Women were administered the 28-day, combination OC (20 microg EE/100 microg LNG; 21 days active medication/7 days placebo) for up to 3 years.
View Article and Find Full Text PDF